

ABSTRACT

The object of the present invention is to provide a pharmaceutical composition or a method that is effective for treating myotonic dystrophy type 1 (DM1). Provided is a therapeutic drug or method for DM1 that utilizes a modified PPR protein.

[Selected Drawing] Figure 2